FCGR2B and Allergy: We hypothesize that administration of a chimeric molecule, composed of a monoclonal 2.4G2 antibody against FcγRIIb coupled with a Der p1-derived peptide (Dp52–71), can selectively eliminate disease-associated allergen-specific B cells in a chronic mouse model of HDM allergy.